QTX3046 in Patients With KRAS G12D Mutations
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Advanced Solid Tumor
DRUG: QTX3046|COMBINATION_PRODUCT: Cetuximab
Number of participants with Treatment-emergent Adverse Events (TEAEs), Define as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab., up to 2 years|Number of participants with Dose Limiting Toxicities (DLTs), DLTs will be defined as the occurrence of any of the toxicities as described in the protocol., up to 21 days
Area under the plasma concentration-time curve (AUC) of QTX3046, Plasma concentration data for QTX3046 will be used to evaluate the area under the plasma concentration-time curve (AUC) of QTX3046, up to 2 years|Peak plasma concentration of QTX3046 (Cmax), Plasma concentration data for QTX3046 will be used to evaluate peak plasma concentration (Cmax) of QTX3046, up to 2 years|Objective response rate (ORR), The ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on RECIST 1.1., up to 2 years|Duration of response (DoR), Duration of response (DoR) is defined as the time between first evidence of objective response and disease progression (as measured by RECIST 1.1) or death, whichever occurs earlier, in subjects who achieve CR or PR., up to 2 years
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.